High dose intravenous gammaglobulin and platelet transfusions in leukaemic HLA-immunized patients.
3 aplastic patients with acute leukaemia, strongly HLA-immunized and refractory to platelet transfusions, received polyvalent gammaglobulin i.v. infusions (0.4 g/kg/d for 5 or 6 d) in association with daily random platelet transfusions. Platelet recovery was obtained in 2 patients. The 3rd patient did not show any significant rise in platelet count. The ability of gammaglobulin to prolong the life-span of incompatible transfused platelets could facilitate the management of HLA-immunized patients.
D000328:Adult; D001792:Blood Platelets / Q000276:immunology; D001803:Blood Transfusion; D002470:Cell Survival / Q000187:drug effects*; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D006680:HLA Antigens / Q000276:immunology; D006801:Humans; D007114:Immunization; D007275:Injections, Intravenous; D007518:Isoantibodies / Q000032:analysis; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000276:immunology; D008297:Male; D017713:Platelet Transfusion; D011247:Pregnancy; D005719:gamma-Globulins / Q000008:administration & dosage / Q000627:therapeutic use*
D006680:HLA Antigens; D007518:Isoantibodies; D005719:gamma-Globulins